Associated Papers
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer.
Morganti S et al.
Npj Breast Cancer, 2024
38627457 (PubMed )
Supplement: 41523_2024_632_MOESM1_ESM.pdf
Select a paper to view details